Key Highlights

  • Hemab Therapeutics Holdings (NASDAQ:COAG) traded at USD 44.30 in a published market data snapshot dated November 5, 2026, up 43.77% over one month and 13.90% over one week, placing it among the stronger mid caps.
  • The one month surge sits inside a volatile path: shares rose 72.09% over six months, yet they are down 15.64% over three months.
  • The IPO priced on April 30, 2026 at USD 18 for 16.8 million shares, upsized from 11.8 million and raising about USD 302 million, so the USD 44.30 price sits 146% above the offer (calculated).
  • The latest session fell 1.76%, and no single catalyst was identified for the month, so the move is framed here as a mix of pipeline sentiment and general small and Mid cap biotech dynamics.

Price Path Since the April Listing

The November 5, 2026 snapshot places Hemab Therapeutics Holdings (NASDAQ:COAG) at USD 44.30, a one month gain of 43.77% and a one week gain of 13.90%, which puts it in the USD 2 billion to USD 10 billion mid cap bucket. The latest session slipped 1.76%, so part of the run was handed back. Three month shares are down 15.64%, six month shares are up 72.09%, and no year to date figure was visible. The stock began trading on Nasdaq under COAG after pricing on April 30, 2026 at USD 18, the top of a USD 16 to USD 18 range. Goldman Sachs, Jefferies and Evercore ISI were joint bookrunners. A published release from Novo Holdings put the first day close at nearly 90% above the offer price.

Sutacimig Pipeline Milestones and the Missing Trigger

No single catalyst was identified for the past month, and no Earnings release, trial readout or filing dated within the window was confirmed. The pipeline is the documented piece. Sutacimig, formerly HMB-001, is a subcutaneous bispecific antibody aimed at Glanzmann thrombasthenia. In March 2026 the FDA awarded it Breakthrough Therapy status, following a Phase I/II study. The offering documents describe a completed Phase 2, with a Phase 3 in Glanzmann thrombasthenia and a Phase 2 in Factor VII deficiency still ahead. HMB-002 is in Phase 1/2 for von Willebrand disease. As general context, young biotechs often re-rate once analyst initiations arrive after quiet periods, and a thin float after an IPO can amplify moves. These are mechanisms, not confirmed causes here.

Pre-Revenue Valuation and Float Risks at USD 44.30

No commercial Revenue appears in the figures located, so price to sales and P/E are not meaningful, leaving the pipeline to carry valuation. A 52-week range and average Volume could not be confirmed, so neither is quoted. A recent IPO can carry a modest public float, which means a small number of trades can move the price and spreads can be wide. At USD 44.30 the shares sit 146% above their USD 18 Offer Price (calculated), so expectations are high. A 43.77% monthly rise can reverse as quickly as it formed, and the 15.64% three month decline shows that already happened once. Clinical setbacks, a Phase 3 delay, financing needs and lock-up expirations are the specific risks for a pre-revenue biotech.

Where Things Stand

The jump in Hemab Therapeutics Holdings (NASDAQ:COAG) appears to reflect pipeline momentum and sector flows rather than one confirmed catalyst. Trading at USD 44.30 after a 43.77% monthly rise and a 13.90% weekly rise, it ranks among the strongest mid caps in a published market data snapshot dated November 5, 2026. The 15.64% three month decline and the 1.76% latest session dip show how uneven the path has been, and nothing here implies the move will continue.